Corvus Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CRVS Nasdaq 2830 www.corvuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Jan 13th, 2025 12:30 pm
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 9:01 pm
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn - Jan 7th, 2025 2:18 pm
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - Dec 18th, 2024 6:23 pm
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell - Dec 18th, 2024 1:31 pm
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Dec 18th, 2024 12:30 pm
Tessera gets sickle cell funding; Corvus shares slide on eczema data - Dec 18th, 2024 11:45 am
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Dec 17th, 2024 9:01 pm
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% - Dec 11th, 2024 12:06 pm
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity - Dec 4th, 2024 9:05 pm
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - Nov 14th, 2024 3:01 pm
An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued - Nov 14th, 2024 11:39 am
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... - Nov 13th, 2024 7:18 am
Corvus: Q3 Earnings Snapshot - Nov 12th, 2024 9:13 pm
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Nov 12th, 2024 9:01 pm
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer - Nov 9th, 2024 6:40 pm
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 - Nov 5th, 2024 9:02 pm
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment - Oct 17th, 2024 12:46 pm
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug - Sep 11th, 2024 2:47 pm
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma - Sep 10th, 2024 12:30 pm